Vanderbilt researchers created the first selective compound designed to inhibit TAOK-1, a poorly understood protein connected to Alzheimer’s disease. They also discovered a second compound that activates the entire TAOK protein family, offering scientists an unexpected new research tool. Together, the compounds could reveal hidden disease mechanisms and point toward new treatment strategies.